Chemoprevention of breast cancer with fenretinide

R. Torrisi, A. Decensi, F. Formelli, T. Camerini, G. De Palo

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Chemoprevention of cancer represents a challenge for oncology during this new millennium. Substantial advances have been accomplished in the last decade, especially for primary and secondary prevention of breast cancer. In addition to tamoxifen, raloxifene and other selective estrogen receptor modulators, retinoids are among the most promising agents, given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide, the synthetic amide of retinoic acid, inhibits cell growth mostly through the induction of apoptosis with mechanisms which may partly involve the retinoid receptors. Because it has a favourable toxicological profile, fenretinide has been extensively investigated in clinical trials. A large randomised phase III trial for secondary breast cancer prevention has been recently carried out in Italy. Results showed a reduction of second breast malignancies in premenopausal women. In addition, a significant decrease of circulating insulin-like growth factor (IGF)-1, a known risk factor for premenopausal breast cancer, was observed after 1 year of fenretinide administration in premenopausal women with breast cancer. Ongoing studies on the validation of the circulating IGF-1 as a surrogate endpoint biomarker of fenretinide activity and on the effectiveness of the combination with low dose tamoxifen may provide further insight into the future clinical application of fenretinide.

Original languageEnglish
Pages (from-to)909-918
Number of pages10
JournalDrugs
Volume61
Issue number7
Publication statusPublished - 2001

Fingerprint

Fenretinide
Chemoprevention
Breast Neoplasms
Retinoids
Somatomedins
Tamoxifen
Breast
Biomarkers
Selective Estrogen Receptor Modulators
Oncology
Second Primary Neoplasms
Validation Studies
Cell growth
Primary Prevention
Secondary Prevention
Tretinoin
Amides
Toxicology
Italy
Carcinogenesis

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Torrisi, R., Decensi, A., Formelli, F., Camerini, T., & De Palo, G. (2001). Chemoprevention of breast cancer with fenretinide. Drugs, 61(7), 909-918.

Chemoprevention of breast cancer with fenretinide. / Torrisi, R.; Decensi, A.; Formelli, F.; Camerini, T.; De Palo, G.

In: Drugs, Vol. 61, No. 7, 2001, p. 909-918.

Research output: Contribution to journalArticle

Torrisi, R, Decensi, A, Formelli, F, Camerini, T & De Palo, G 2001, 'Chemoprevention of breast cancer with fenretinide', Drugs, vol. 61, no. 7, pp. 909-918.
Torrisi R, Decensi A, Formelli F, Camerini T, De Palo G. Chemoprevention of breast cancer with fenretinide. Drugs. 2001;61(7):909-918.
Torrisi, R. ; Decensi, A. ; Formelli, F. ; Camerini, T. ; De Palo, G. / Chemoprevention of breast cancer with fenretinide. In: Drugs. 2001 ; Vol. 61, No. 7. pp. 909-918.
@article{4d34de5d4ec5432fbe7460bc5fe9a86a,
title = "Chemoprevention of breast cancer with fenretinide",
abstract = "Chemoprevention of cancer represents a challenge for oncology during this new millennium. Substantial advances have been accomplished in the last decade, especially for primary and secondary prevention of breast cancer. In addition to tamoxifen, raloxifene and other selective estrogen receptor modulators, retinoids are among the most promising agents, given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide, the synthetic amide of retinoic acid, inhibits cell growth mostly through the induction of apoptosis with mechanisms which may partly involve the retinoid receptors. Because it has a favourable toxicological profile, fenretinide has been extensively investigated in clinical trials. A large randomised phase III trial for secondary breast cancer prevention has been recently carried out in Italy. Results showed a reduction of second breast malignancies in premenopausal women. In addition, a significant decrease of circulating insulin-like growth factor (IGF)-1, a known risk factor for premenopausal breast cancer, was observed after 1 year of fenretinide administration in premenopausal women with breast cancer. Ongoing studies on the validation of the circulating IGF-1 as a surrogate endpoint biomarker of fenretinide activity and on the effectiveness of the combination with low dose tamoxifen may provide further insight into the future clinical application of fenretinide.",
author = "R. Torrisi and A. Decensi and F. Formelli and T. Camerini and {De Palo}, G.",
year = "2001",
language = "English",
volume = "61",
pages = "909--918",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "7",

}

TY - JOUR

T1 - Chemoprevention of breast cancer with fenretinide

AU - Torrisi, R.

AU - Decensi, A.

AU - Formelli, F.

AU - Camerini, T.

AU - De Palo, G.

PY - 2001

Y1 - 2001

N2 - Chemoprevention of cancer represents a challenge for oncology during this new millennium. Substantial advances have been accomplished in the last decade, especially for primary and secondary prevention of breast cancer. In addition to tamoxifen, raloxifene and other selective estrogen receptor modulators, retinoids are among the most promising agents, given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide, the synthetic amide of retinoic acid, inhibits cell growth mostly through the induction of apoptosis with mechanisms which may partly involve the retinoid receptors. Because it has a favourable toxicological profile, fenretinide has been extensively investigated in clinical trials. A large randomised phase III trial for secondary breast cancer prevention has been recently carried out in Italy. Results showed a reduction of second breast malignancies in premenopausal women. In addition, a significant decrease of circulating insulin-like growth factor (IGF)-1, a known risk factor for premenopausal breast cancer, was observed after 1 year of fenretinide administration in premenopausal women with breast cancer. Ongoing studies on the validation of the circulating IGF-1 as a surrogate endpoint biomarker of fenretinide activity and on the effectiveness of the combination with low dose tamoxifen may provide further insight into the future clinical application of fenretinide.

AB - Chemoprevention of cancer represents a challenge for oncology during this new millennium. Substantial advances have been accomplished in the last decade, especially for primary and secondary prevention of breast cancer. In addition to tamoxifen, raloxifene and other selective estrogen receptor modulators, retinoids are among the most promising agents, given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide, the synthetic amide of retinoic acid, inhibits cell growth mostly through the induction of apoptosis with mechanisms which may partly involve the retinoid receptors. Because it has a favourable toxicological profile, fenretinide has been extensively investigated in clinical trials. A large randomised phase III trial for secondary breast cancer prevention has been recently carried out in Italy. Results showed a reduction of second breast malignancies in premenopausal women. In addition, a significant decrease of circulating insulin-like growth factor (IGF)-1, a known risk factor for premenopausal breast cancer, was observed after 1 year of fenretinide administration in premenopausal women with breast cancer. Ongoing studies on the validation of the circulating IGF-1 as a surrogate endpoint biomarker of fenretinide activity and on the effectiveness of the combination with low dose tamoxifen may provide further insight into the future clinical application of fenretinide.

UR - http://www.scopus.com/inward/record.url?scp=0034992191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034992191&partnerID=8YFLogxK

M3 - Article

C2 - 11434448

AN - SCOPUS:0034992191

VL - 61

SP - 909

EP - 918

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 7

ER -